<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159313</url>
  </required_header>
  <id_info>
    <org_study_id>17306</org_study_id>
    <secondary_id>2013-005166-18</secondary_id>
    <nct_id>NCT02159313</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study</brief_title>
  <official_title>Relative Bioavailability Study of Riociguat Given Orally as a Crushed 2.5 mg Tablet Suspended in Applesauce, Crushed 2.5 mg Tablet Suspended in Water, and Whole 2.5 mg Tablet After a Continental Breakfast in Comparison to a Whole 2.5 mg Tablet Given in the Fasted State to Characterize the Pharmacokinetic Properties in Healthy Male Adult Subjects in a 4-fold Crossover Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate relative bioavailability of crushed tablets suspended in apple sauce or water
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of riociguat in plasma by Area under the plasma concentration time curve (AUC)</measure>
    <time_frame>Multiple time points up to day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of riociguat in plasma by maximal concentration (Cmax)</measure>
    <time_frame>Multiple time ponits up to day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BAY63-2521 with Non sparkling water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of a whole 2.5 mg riociguat tablet (fasted) with 240 mL of non-sparkling water at room temperature</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY63-2521 with applesauce</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of a crushed 2.5 mg riociguat tablet suspended in 50 mL applesauce, to be eaten with a spoon (fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY63-2521 with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of a crushed 2.5 mg riociguat tablet suspended in a glass with 25 mL water, to be drunk and flushed twice with 25 mL water in the same glass (fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY63-2521 after breakfast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of a whole 2.5 mg riociguat tablet taken within 5 minutes after the last bite of a continental breakfast (fed) with 240 mL of non-sparkling water at room temperature</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat(Adempas,BAY63-2521)</intervention_name>
    <description>Single dose of a whole 2.5 mg riociguat tablet</description>
    <arm_group_label>BAY63-2521 with Non sparkling water</arm_group_label>
    <arm_group_label>BAY63-2521 with applesauce</arm_group_label>
    <arm_group_label>BAY63-2521 with water</arm_group_label>
    <arm_group_label>BAY63-2521 after breakfast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject

          -  Age: 18 to 45 years (inclusive) at the first screening examination

          -  Ethnicity: white

          -  Body mass index (BMI): &gt;18 and &lt;29.9 kg/m2

        Exclusion Criteria:

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination, or effects of the study drug will
             not be normal

          -  History of coronary artery disease

          -  Symptomatic postural hypotension (e.g. dizziness, lightheadedness)

          -  History of bronchial asthma or any other airway disease

          -  Smoking (former smokers who have stopped smoking at least 3 months before the first
             study drug administration may be included)

          -  Clinically relevant findings in the ECG such as a second- or third-degree
             atrioventricular block, prolongation of the QRS complex over 120 ms or of the QTc
             interval (QT interval corrected for heart rate) over 450 ms

          -  Systolic blood pressure below 100 or above 145 mmHg

          -  Diastolic blood pressure below 50 or above 95 mmHg

          -  Heart rate below 45 or above 95 beats per minute
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>MÃ¶nchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here and search for websynopsis results</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biological Availability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

